Data of GBG research projects were presented at ESMO 2019, September 27th to October 1st in Barcelona.
Abstract #4332, Poster Board #180PD
Poster discussion Date: 28.09.2019; Time: 15:10 - 15:25 (Invited Discussant 179PD, 180PD and 181PD), Poster Discussion - Breast cancer, early stage, Location: Valencia Auditorium (Hall 5)
Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free
survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC)
J. Furlanetto, V. Nekljudova, A. Schneeweiss et al.
Abstract #4042, Poster Board #182PD
Poster discussion Date: 28.09.2019; Time: 15:35 - 15:50 (Invited Discussant 182PD, 183PD, 184PD and 185PD). Poster Discussion - Breast cancer, early stage, Location: Valencia Auditorium (Hall 5)
Utility of the CPS+EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy
F. Marmé, C. Solbach, L. Michel et al.
Abstract #3792, Poster Board #188P,
Poster Date: 29.09.2019; Time: 12:00 - 13:00, Poster Display session 2, Location: Poster Area (Hall 4)
Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: pooled analysis of prospective neoadjuvant breast cancer (BC) trials
G. Werutsky, M. Untch, C. Hanusch et al.
Abstract #3928. Poster Board #195P.
Poster Date: 29.09.2019; Time: 12:00 - 13:00
Poster Display session 2 , Location: Poster Area (Hall 4)
Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study
H. Tesch, S. Loibl, K. Kast et al.
LBA19 Date: 30.09.2019 , Time: 15:00 - 15:15, Proffered Paper - Breast cancer, early stage, Location: Cordoba Auditorium (Hall 7)
Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: an update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC)
M. Untch, C. Geyer, C. Huang et al.